




PROCEPT[®]
BIOBOTICS

INVESTOR EVENT

2023 American Urology Association
Annual Meeting

April 28, 2023





Safe Harbor Statement

This presentation and accompanying oral presentation contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including the expected financial results of PROCEPT BioRobotics Corporation (the “Company”). Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “anticipates,” and “future” or similar expressions are intended to identify forward-looking statements. Any forward-looking statements made by us in this presentation speaks only as of the date on which it was made and are based on management’s current expectations of future events, assumptions, estimates, and beliefs, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those described in the forward-looking statements include, among others: (i) the rate and degree of market acceptance of the AQUABEAM Robotic System and Aquablation therapy and descriptions of the Company’s revenues, gross margin, profitability, operating expenses, or installed base growth, (ii) the establishment and maintenance of consistent and favorable payment policies for Aquablation therapy, (iii) the rate of growth of the commercial sales and marketing organization and the ability to manage this anticipated growth, (iv) the impact on volumes of elective procedures performed by health care providers and hospital medical device budgets, (v) the effects of increased competition as well as innovations by new and existing competitors in the market for treatments for benign prostatic hyperplasia, (vi) the ability to obtain the required regulatory approvals and clearances to market and sell the AQUABEAM Robotic System in certain other countries, (vii) the development and protection of future innovation, (viii) dependence on a limited number of third-party suppliers for components of the AQUABEAM Robotic System, and (ix) the maintenance of intellectual property rights and the ability to operate the business without infringing the intellectual property rights and proprietary technology of third parties.

This presentation and the accompanying oral presentation also contain estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we compete are necessarily subject to a high degree of uncertainty and risk.

Factors that could cause actual results to differ materially from those contemplated in this presentation can be found in the Risk Factors section of the Company’s public filings with the Securities and Exchange Commission (“SEC”), including the Annual Report on Form 10-K filed with the SEC on February 28, 2023 and any current and periodic reports filed thereafter, available at www.sec.gov.

Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical fact are forward-looking statements. Except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ from those set forth in this presentation due to the risks and uncertainties inherent in the Company’s business. In light of the foregoing, investors are urged not to rely on any forward-looking statement or third-party data in reaching any conclusion or making any investment decision about any securities of the Company.

This presentation regarding the Company shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Sales and offers to sell PROCEPT BioRobotics securities will only be made in accordance with the Securities Act of 1933, as amended, and applicable SEC regulations, including prospectus requirements.



Proven Executive Leadership Team



REZA ZADNO, PhD

President &
CEO

Avedro, Visiogen,
PercuSurge, Cardiac
Pathways



KEVIN WATERS

EVP, Chief Financial
Officer

Accuray, Conceptus,
Laserscope
(Greenlight), VISX



SHAM SHIBLAQ

EVP, Chief
Commercial Officer

Intuitive Surgical,
Conceptus, Invuity,
Analogic



BARRY TEMPLIN

SVP, Clinical &
Medical Affairs

Abbott Vascular,
Guidant, GE Aircraft
Engines



Agenda

1

Introduction – 10 min

Reza Zadno, CEO

2

Financial Review – 5 min

Kevin Waters, CFO

3

Commercial Strategy – 10 min

Sham Shiblaq, Chief Commercial Officer

4

Surgeon Panel with Q&A – 60 min

Dr. Dean Elterman / Dr. Brian Helfand / Dr. Jonathan Pavlinec







Benign Prostatic Hyperplasia (BPH)

A Significant Men's Health Disease in the U.S.

NORMAL PROSTATE



ENLARGED PROSTATE (BPH)



#1 Reason men visit the urologist




1 in 2 Estimated men ages 51-60 have BPH and prevalence increases over time



99% Men with BPH say symptoms impact Quality of Life



~40M Men in the U.S. that currently have BPH



2x Men >65 years old in the U.S. expected to double in the next 10 years


Roehrborn, CG, Rosen, RC. Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily. *Clinical Interventions in Aging* 2008;3(3).
 Bouhadana, et al. Patient Perspectives on Benign Prostatic Hyperplasia Surgery: A Focus on Sexual Health. *J Sex Med* 2020;1 – 5
 2014, Ortman, An Aging Nation: The Older Population in the United States

Loughlin, K. Benign prostatic hyperplasia: epidemiology, economics and evaluation. *Can J Urol.* 2015 Oct;22 Suppl 1:1-6.
 Vuichoud, C, Loughlin, K. Benign prostatic hyperplasia: epidemiology, economics and evaluation. *Can J Urol.* 2015 Oct;22 Suppl 1:1-6.
 MS Health NDTI Urology Specialty Profile, July 2012-June 2013



Large Market & Significant Unmet Need

U.S. men actively **MANAGED** for BPH



12M

4.3M

WATCHFUL WAITERS

- ▶ Choose to do nothing and suffer BPH symptoms

6.7M

PHARMACEUTICALS

- ▶ Suffer dosing adjustments and side effects

\$16B

1.1M

PHARMACEUTICAL FALLOUT

- ▶ Delay surgery despite medication failure

\$3B

400K

SURGERIES PER YEAR

- ▶ Compromise between safety and efficacy outcomes

\$1B

8.2M

Actively **TREATED** for BPH



~\$20B

U.S. BPH Surgical Market Opportunity

All numbers are approximate.

Vuichoud, C, Loughlin, K. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015 Oct;22 Suppl 1:1-6.

Data on File, PROCEPT BioRobotics


Total surgeries based on 2019 market data, representing pre-pandemic surgeries

Copyright 2023 PROCEPT BioRobotics Corporation. All Rights Reserved.



Unmet Need in Surgical Intervention

UNMET NEED:
SAFETY & EFFICACY IN ALL PROSTATES
ALL SIZES, ALL SHAPES



BPH size ranges: AUA Guidelines: Surgical Management of BPH/Lower Urinary Tract Symptoms (2018, amended 2019, 2020) Published 2018, Amended 2019, 2020.

Tanneru et al: An Indirect Comparison of Newer Minimally Invasive Treatments for Benign Prostatic Hyperplasia: A Network Meta-Analysis Model, Journal of Endourology, 2020

PVP = Photovaporization of Prostate

MIST: Minimally Invasive Surgical Technology

Copyright 2023 PROCEPT BioRobotics Corporation. All Rights Reserved.



Aquablation Therapy with the AquaBeam Robotic System

Only Image-Guided, Automated Robotic Therapy for BPH


EFFECTIVE, SAFE
AND DURABLE
OUTCOMES THAT
ARE INDEPENDENT
OF PROSTATE SIZE,
SHAPE, AND
SURGEON
EXPERIENCE

AQUABEAM®
— ROBOTIC SYSTEM —




Real-Time Image Guidance

Intraoperative ultrasound imaging combined with cystoscopic visualization provide a multidimensional view of the treatment area



Personalized Treatment Planning

Advanced planning software allows the surgeon to map the treatment contour that precisely targets the resection area



Automated Robotic Execution

The robot executes the treatment plan and guides the precisely calibrated waterjet with speed and accuracy while surgeon monitors



Heat-Free Waterjet Resection


Utilizing the unique power of a pulsating waterjet near the speed of sound, Aquablation therapy removes prostatic tissue with a heat-free waterjet



Aquablation Treated Prostate Sizes – U.S.

PROSTATE SIZE HISTOGRAM – U.S. DATA

1/1/21 to 3/31/23



Vision

Become the BPH treatment standard of care and expand the market.

Immediate Strategy


Convert TURP & PVP hospital-base procedures (50-100 mL) and then drive to smaller glands.

~70% of Prostates treated are <100ml



FINANCIAL REVIEW

KEVIN WATERS
Chief Financial Officer





Significant Progress Since 1Q21

Total Revenue

(\$-Million)

\$7.2 > **\$24.4**
Q1'21 Q1'23

+3.4X

% Access to Aquablation¹

(U.S.)

50% > **95%**
Q1'21 Q1'23

+1.9X

Monthly Utilization

(U.S.)

3.1 > **6.4**
Q1'21 Q1'23

+2.1X

Total Employees

185 > **476**
Q1'21 Q1'23

+2.6X

U.S. Install Base

69 > **192**
Q1'21 Q1'23

+2.8X

New Surgeon Retention

(by Quarter in U.S.)

82% > **94%**
Q1'21 Q1'23

+15%




- ✓ Sign contracts with majority of **large IDNs** by 12/31/23
- ✓ Increased **Reimbursement** in UK
- ✓ **Two FDA Studies with 5-Year Data**
- ✓ Meaningful **expansion** of U.S. **Commercial team**
- ✓ **4x** increase in manufacturing & cleanroom space
- ✓ **92 Net Promoter Score²**

(1) United Healthcare announced positive coverage of Aquablation Therapy on April 1, 2023, with an effective date of June 1, 2023

(2) Results based on PRCT customer survey




1Q23 Earnings Recap





2023 Financial Guidance

Total Revenue (\$M)



	Actual 2022	Guidance FY23 ¹
Revenue	\$75.0 million	\$128.0 million
<i>Revenue growth (y/y)</i>	<i>118%</i>	<i>~71%</i>
Gross Margin	49%	54%
Operating Expenses	\$117.8 million²	\$167.0 million³
Adjusted EBITDA Loss	\$68.0 million⁴	\$70.5 million⁴

TOTAL CASH & CASH EQUIVALENTS BALANCE OF \$181M AND DEBT BALANCE OF \$52M AS OF MARCH 31, 2023


(1) 2023 financial guidance updated on April 27, 2023
 (2) 2022 operating expenses included approximately \$10.4 million in stock-based compensation expense
 (3) 2023 operating expense guidance includes approximately \$22.1 million in stock-based compensation expense
 (4) See appendix for reconciliation of non-GAAP financial measures



PROCEPT[®]
BIOBOTICS

COMMERCIAL STRATEGY

SHAM SHIBLAQ
Chief Commercial Officer






U.S. Commercial Opportunity: Segmentation

Target High-Volume Hospitals

US HOSPITALS BY ANNUAL BPH RESECTIVE VOLUME (2019)

~2,700 Total Resective Hospitals




INITIAL TARGET
860 High Volume Hospitals
Annual Resective Volume ≥100

~180K Resective Procedures
Avg. Annual Resective Volume = 200
Monthly Avg. = 17.4

RESECTIVE PROCEDURE SHARE BY HOSPITAL TYPE (2019)

>250,000 Hospital Based Resective Procedures



- HIGH (≥100 procedures)
- LOW (<100 procedures)

30% OF HOSPITALS GENERATE 70% OF RESECTIVE BPH PROCEDURES



Sales Pipeline Explained

Robotic Sales Rep (Capital)
Targets



2,700
BPH Hospital Targets



RSR **initial relationship development**
with surgeon

Phase Zero Pipeline



RSR **partners with surgeon champion**
Assign **confidence interval** to close

Phase 1+ Pipeline



Agree to contract terms,
opportunity exits funnel and
system is shipped to customer

Unit Sales





Sales Pipeline Process

PHASE 1

Partner with a Surgeon Champion

Identify surgeon champion with executive access

Leverage peer to peer programs to nurture lead development and gain commitment

PHASE 2

Present Aquablation Program to Execs

Illustrate Clinical and Economic value propositions

Quantify Market Development opportunity

PHASE 3

Funds Approved and Contract Negotiation

Leverage regional or national contracts, if applicable

PHASE 4

Acquisition




Set impending events (e.g. scheduling patients)

Coordinate cross-functional program launch (capital, utilization, HE&R, Marketing)

Once deal enters funnel, high probability to close in 6 to 9 months



IDN Market Segmentation



- Single Site or No IDN
- Small IDNs (2-9)
- Medium IDNs (10-19)
- Strategic IDNs (>=20)


17 Strategic IDNs account for ~29% of BPH hospitals and ~26% of high-volume centers



Meaningful Opportunity to Continue U.S. Territory Expansion

860 High Volume Hospitals

65% High Volume Hospitals within 100-mile radius of Robotic Sales Reps



● High Volume Hospital \leq 100 mile radius of Robotic Sales Representative

● High Volume Hospital $>$ 100 mile radius of Robotic Sales Representative

Data on File, PROCEPT BioRobotics
Hospitals and Procedures based on 2019 market data, representing pre-pandemic surgeries

Copyright 2023 PROCEPT BioRobotics Corporation. All Rights Reserved.



2023 Capital Sales Tailwinds

2023 Tailwinds



**Expanded
Capital Rep
Team**



**United
Healthcare
Coverage**
(Effective 6/1/23)



**Transitional
Passthrough
Payment
Extended**
(Expires 12/31/23)



**16 New Capital
Territories**
(As at 12/31/22)



**Strong and
Growing Sales
Funnel**



**Signed Largest
National IDN
Sales Contract**
(Effective 4/1/23)



Key International Market Development Summary

First and only robotics company to receive MIB from NICE
Direct sales force
~\$8,000 procedure reimbursement



Expanding clinical data with WATER III Study
Direct sales force in France and Germany
Strong distributor presence in Italy and Spain



Regulatory approval in 1Q22
Enrolling Post Market Approval Study in 2H23
Full commercial launch anticipated in late 2024



Regulatory process underway






PROCEPT[®]
BIOBOTICS

SURGEON PANEL

2023 American Urology Association
Annual Meeting

April 28, 2023





Introductions



Dean Elterman, MD

University of Toronto

Toronto, Canada



Brian Helfand, MD, PhD

North Shore University
Health System

Chicago, IL



Jonathan Pavlinec, MD

Florida Urology Partners,
HCA South Shore Hospital

Tampa, FL



Disclosures



Dean Elterman, MD

University of Toronto

Toronto, Canada

Grants/Research Support: Boston Scientific

Speakers Bureau/Honoraria: AbbVie Astellas, Boston Scientific, Medtronic, PROCEPT BioRobotics, Prodeon, Zenflow

Consulting: Medtronic, BSCI, Coloplast, Rivermark, PROCEPT BioRobotics

Investigator: BSCI, Olympus, Prodeon, Zenflow, Medtronic, Rivermark, PROCEPT BioRobotics, Proverum


The views expressed in this presentation are those of the presenter and do not necessarily reflect the views or policies of PROCEPT BioRobotics or its subsidiaries. No official endorsement by PROCEPT BioRobotics or any of its subsidiaries of any vendor, products or services contained in this presentation is intended or should be inferred

An honorarium is provided by PROCEPT BioRobotics to the speakers for this presentation




Aquablation is Superior to TURP Treating 50-80mL Prostates^{1,2}


IPSS Reduction



5 Year Retreatment Rate



MSHQ-EjD



Aquablation Therapy yields better long-term efficacy and safety outcomes than TURP for prostate volumes of 50-80mL

(1) 2022 Gilling et al WATER 5yr

(2) EAU 2023, Aquablation Therapy vs TRUP: 5-year outcomes of the WATER Randomized Clinical Trial for Prostate Volume 50-80mL



WATER II - Five Year Efficacy Results Aquablation 5 Year Cohort

IPSS improvement 15.9, $p < 0.0001$





IPSS baseline (SD) 22.6 (6.4)

IPSS at 60-months (SD) 6.8 (4.6)

Qmax improvement 9.2, $p < 0.0001$

Qmax baseline, mL/sec (SD) 8.6 (3.4)


Qmax 60-mo, mL/sec (SD) 17.1 (9.8)



At 5-year prospective follow-up, Aquablation was shown to be safe and effective in men with large prostates (80-150mL)



WATER II – Freedom from Secondary BPH Intervention at 5yrs¹




96.3%
of patients avoided a secondary intervention due to recurrent symptoms



Aquablation Postoperative Bleeding Risk Reduction

Comparison of Bleeding Risk Requiring Intervention for Aquablation Procedures¹



~13,500 Aquablation cases were performed with a mean prostate size of 90mL

Focal bladder neck cautery protocol introduced in January 2020

Significant decline in bleeding risk requiring an intervention





In 2022, **risk of transfusion** was reduced to **0.2%**

Following adoption of the standardized hemostasis technique, bleeding risk has declined 10-fold and allowing some surgeons the option of day-case Aquablation.



Clinically Validated Efficacy, Durability and Safety Independent of Prostate Size and Shape

Meta-Analysis

Clinical studies	4
Patients	425
Prostate volume	20 – 150 mL
1 year follow up	   
Analysis of sub-groups	<ol style="list-style-type: none"> Above or below 100 mL Absence or presence of obstructive median lobe <p>Remarkable improvements across prostates all sizes and shapes</p>


Average Results Across All Sub-Groups

IPSS improvement	16 points
Urinary peak flow rate	20.5 mL/sec
Quality of life improvement	3.3 points
Post void residual improvement	62 mL
Ejaculatory dysfunction	10.8%
Erectile dysfunction	0%
Incontinence	0.5%



Meta Analysis


Remarkable improvements across prostates of all sizes and shapes





Meta Analysis

Remarkable improvements across prostates of all sizes and shapes





Disclosures



Brian Helfand, MD, PhD

North Shore University
Health System

Chicago, IL

Consulting: PROCEPT BioRobotics

Network investigator: NIH LURN lower urinary tract dysfunction

The views expressed in this presentation are those of the presenter and do not necessarily reflect the views or policies of PROCEPT BioRobotics or its subsidiaries. No official endorsement by PROCEPT BioRobotics or any of its subsidiaries of any vendor, products or services contained in this presentation is intended or should be inferred

An honorarium is provided by PROCEPT BioRobotics to the speakers for this presentation




Aquablation Therapy: An All-in-One Solution

THEN



NOW





Simplified Treatment Algorithm Improves Practice Efficiency

THEN...

Patient counseling requires a *Treatment Algorithm*

- ▶ Size
- ▶ Median Lobe
- ▶ Anterior Tissue
- ▶ Antithrombotics
- ▶ Catheter Duration
- ▶ Antegrade Ejaculation
- ▶ Durability
- ▶ Catheter Duration

NOW...

***Treatment Algorithm* not needed**

- ▶ Patient counseling simplified
- ▶ Practice consolidation



Surgeons to Limit Pharmaceutical Therapy in Future



MINIMAL
IMPACT ON
SYMPTOMS &
HIGH SIDE
EFFECT PROFILE

- Minimal impact on symptom relief (IPSS reduction: ~5 points) and flow improvement (~2.5 mL/s improvement)
- Side effects may include **ejaculatory dysfunction, erectile dysfunction**, headaches, dizziness, and loss of libido
- Long-term use increases risk of cardiac failure and dementia
- Long-term use increases risk of severe bladder damage
- **Up to 30%** of patients **stop BPH medication** within 2 years

Given the growing aging population, surgeons want to offer a “one and done” solution to minimize retreatment rates

MTOPS study, NEJM December 2003, Vol.349, No.25

Lusty et al. Cardiac Failure Associated with Medical Therapy of Benign Prostatic Hyperplasia: A Population Based Study / Vol. 205, 1430-1437, May 2021

Bortnick et al. Long-term Consequences of Medical Therapy for Benign Prostatic Hyperplasia / Rev Urol. 2019;21(4):154-157.


Failure to continue meds based on Kaplan Factors in Predicting Failure With Medical Therapy for BPH, Rev Urol. 2005;7(suppl 7):S34-S39.

IPSS = International Prostate Symptom Score




Aquablation to Expand Resective Surgery Market

THEN...



NOW...



Surgeons are bypassing Pharmaceuticals and offering Aquablation earlier to men given its durability and safety profile – ultimately **expanding the resective market**




Same Day Discharge with Aquablation Therapy

Day Case Aquablation

If the degree of hematuria was not clinically significant (grades I–III) after clamping irrigation at ~4 hours postoperatively, patients were discharged home. The catheter must be flowing well without clots.

Hematuria Scale





Aquablation Therapy Resident Training Program



AQUABEAM®
— ROBOTIC SYSTEM —


AQUABLATION
RESIDENCY
PROGRAMS ARE
THE NEW
STANDARD

- Younger surgeons prefer to train with novel technologies
- Enhancing skills and use of rectal ultrasound equipment
- Increased emphasis on surgical planning and relevant anatomy
- Surgical standardization to improve patient outcomes

AQUABLATION THERAPY CURRENTLY IN 16 RESIDENCY PROGRAMS ACROSS THE UNITED STATES



Disclosures



Jonathan Pavlinec, MD

Florida Urology Partners,
HCA South Shore Hospital

Tampa, FL

Consulting: PROCEPT BioRobotics

The views expressed in this presentation are those of the presenter and do not necessarily reflect the views or policies of PROCEPT BioRobotics or its subsidiaries. No official endorsement by PROCEPT BioRobotics or any of its subsidiaries of any vendor, products or services contained in this presentation is intended or should be inferred

An honorarium is provided by PROCEPT BioRobotics to the speakers for this presentation



Partnering with Hospital Networks to Launch Aquablation Program

PROCEPT
BIOROBOTICS

Florida Urology
Partners **LLP**



Expand Geographic Reach

Become the premier urology practice in Tampa, FL area. Draw patients from hours away and never refer patients out



Urology Halo Effect

Leverage Prostate Cancer and Kidney Stone practice to offer standardized surgical BPH treatment with Aquablation therapy



Improve Efficiencies

Limit Da Vinci use to radical prostatectomies, while standardizing BPH surgery for Aquablation Therapy



Prioritize Value Based Care

Aquablation Therapy's superior durability results in a one-and-done option for patients



Aquablation Clinical Support Staff

Collaborative

Capital Reps are extremely helpful to hospital administrators

Clinical staff support surgeons in the OR

Collaborative



Strong Clinical Network



Strong Clinical Network

Clinical staff can access nationwide resource network in minutes to address any clinical question

Highly Trained

Highly Trained

Prior to entering the field, every Aquablation Rep is required to complete a rigorous training program and pass a comprehensive surgical exam

Pattern Recognition



Pattern Recognition

Each prostate and case is different

Clinical staff support surgeons in identifying nuanced anatomical patterns



Aquablation Therapy on Path to Become Standard of Care

THEN...

- Exclusively treated large prostates (>120mL) with *Da Vinci* Robot or outside referrals
- Limited OR time due to backlog of *Da Vinci* cases for BPH
- Difficult to balance cancer, complex urolithiasis, and severe BPH cases

NOW...

- Incorporated all surgeon partners to handle increased case load with expansion to multiple sites
- Keep all prostate cases and standardize with *Aquablation Therapy*
- *Aquablation Therapy* frees up time for *Da Vinci* cancer procedures and other OR blocks
- Large increase in BPH patient volume via “word-of-mouth”




All surgeons at Florida Urology Partners are strongly encouraged to **use Aquablation Therapy to improve practice efficiencies** given low learning curve and growing patient supply.



PROCEPT[®]
BIOBOTICS

THANK YOU





Non-GAAP Reconciliations

RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA

(in thousands)

(unaudited)

	Three Months Ended March 31,	
	2023	2022
Net loss	\$ (28,484)	\$ (17,185)
Depreciation and amortization expense	793	758
Stock-based compensation expense	3,724	1,552
Interest (income) and interest expense, net	49	1,385
Adjusted EBITDA	<u>\$ (23,918)</u>	<u>\$ (13,490)</u>

RECONCILIATION OF 2023 GAAP NET LOSS TO ADJUSTED EBITDA Guidance

(in thousands)

(unaudited)

	2023
Net loss	\$ (98,325)
Depreciation and amortization expense	5,050
Stock-based compensation expense	22,125
Interest (income) and interest expense, net	650
Adjusted EBITDA	<u>\$ (70,500)</u>